| Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL) | Asciminib | Phase 1 | Recruiting | Sunil G. Iyer | Nov 13, 2026 |
| Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Asciminib | Phase 1 | Not yet recruiting | City of Hope Medical Center | Nov 3, 2026 |
| A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs | Bosutinib, Nilotinib | Phase 3 | Recruiting | Enliven Therapeutics | Oct 29, 2026 |
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | Imatinib, Nilotinib | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Oct 21, 2026 |
| Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL | Olverembatinib | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Sep 25, 2026 |
| De-escalation Strategy of Tyrosine Kinase Inhibitors Before Treatment Discontinuation in Patients With Chronic Myeloid Leukemia | Imatinib, Nilotinib, Olverembatinib | Phase 4 | Not yet recruiting | Nanfang Hospital, Southern Medical University | Sep 24, 2026 |
| Asciminib Frontline Risk Adapted | Asciminib | Phase 2 | Not yet recruiting | Prof. Dr. med. Andreas Hochhaus | Sep 4, 2026 |
| Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations | Asciminib | Phase 2 | Recruiting | Thomas Ernst, Prof. Dr. med. | Aug 27, 2026 |
| Hyperpolarized MRI for GIST on Imatinib | Imatinib | — | Not yet recruiting | Chang Gung Memorial Hospital | Jul 24, 2026 |
| A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib | Imatinib | Phase 2 | Recruiting | GlaxoSmithKline | Jul 8, 2026 |
| A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region | Asciminib | — | Not yet recruiting | Novartis Pharmaceuticals | Jul 2, 2026 |
| Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines | Asciminib | — | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | Jun 11, 2026 |
| A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) | Ponatinib | Phase 1 | Recruiting | Wake Forest University Health Sciences | May 29, 2026 |
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML | Asciminib | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | May 22, 2026 |
| A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) | Imatinib | Phase 3 | Recruiting | GlaxoSmithKline | May 13, 2026 |
| Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria | Imatinib | Phase 2 | Recruiting | Victoria Biomedical Research Institute | Apr 30, 2026 |
| A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany | Asciminib, Bosutinib, Imatinib, Nilotinib | — | Recruiting | Novartis Pharmaceuticals | Apr 24, 2026 |
| Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis | Imatinib | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | Apr 15, 2026 |
| Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML | Nilotinib | Phase 2 | Not yet recruiting | The University of Hong Kong | Mar 25, 2026 |
| Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL | Olverembatinib | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | Mar 25, 2026 |
| ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL | Olverembatinib | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | Mar 6, 2026 |
| Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL | Olverembatinib | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Mar 2, 2026 |
| Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients | Nilotinib | — | Not yet recruiting | Assiut University | Feb 17, 2026 |
| Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase | Olverembatinib | — | Enrolling by invitation | Qian Jiang | Feb 3, 2026 |
| Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world | Ponatinib | — | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | Jan 21, 2026 |
| Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL | Ponatinib | Phase 2 | Not yet recruiting | University of Alberta | Dec 24, 2025 |
| Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment | Olverembatinib | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | Dec 15, 2025 |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma | Ponatinib | Phase 2 | Recruiting | University of Washington | Nov 4, 2025 |
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) | Olverembatinib | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | Sep 17, 2025 |
| A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy | Bosutinib, Nilotinib | — | Recruiting | Novartis Pharmaceuticals | Jul 29, 2025 |
| A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia | Ponatinib | Phase 2 / Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | Mar 6, 2025 |
| Using Tumor Models to Determine Treatments | Ponatinib | Phase 2 | Recruiting | University Health Network, Toronto | Feb 6, 2025 |
| Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML | Radotinib | — | Active, not recruiting | Il-Yang Pharm. Co., Ltd. | Oct 30, 2024 |
| Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. | Ponatinib | Phase 2 | Recruiting | Novartis Pharmaceuticals | Jul 23, 2024 |
| Study of Olverembatinib (HQP1351) in Patients With CML-CP | Bosutinib | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | May 21, 2024 |
| PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML | Nilotinib | Phase 2 | Recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | May 10, 2024 |
| The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP | Ponatinib | — | Recruiting | Peking University People's Hospital | Apr 30, 2024 |
| A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML). | Bosutinib | — | Recruiting | Pfizer | Mar 7, 2024 |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | Bosutinib | Phase 3 | Active, not recruiting | Novartis Pharmaceuticals | Jul 21, 2021 |
| Asciminib Roll-over Study | Bosutinib | Phase 4 | Recruiting | Novartis Pharmaceuticals | May 7, 2021 |
| Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease | Radotinib | Phase 2 | Active, not recruiting | Il-Yang Pharm. Co., Ltd. | Dec 31, 2020 |
| Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population | Bosutinib | Phase 2 | Active, not recruiting | Baylor College of Medicine | Nov 12, 2020 |
| Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) | Radotinib | Phase 3 | Active, not recruiting | Il-Yang Pharm. Co., Ltd. | Oct 29, 2018 |
| A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs | Radotinib | Phase 3 | Recruiting | Il-Yang Pharm. Co., Ltd. | Mar 9, 2018 |